Re-pigmentation therapy in vitiligo; affects more than 45 million individuals
Clinical and regulatory progress:
- Program announced August 2010
- Trial allowed by FDA in March 2011
- Pilot commenced Q2 2011
- First clinical observations presented at 2011 EADV congress, updated clinical observations presented alongside 2012 AAD Meeting
- Observations from US vitiligo study published
- First treatment results announced December 2012: SCENESSE® successful in Phase IIa vitiligo study
- Further Phase II study commenced in Singapore in May 2014 with preliminary results reported in December 2015
- North American program update published December 2015
To keep up to date with CLINUVEL's progress with vitiligo, go to http://clinuvel.com/products-pipeline/scenesse/vitiligo
Vitiligo is a common skin disorder in which the pigment producing cells of the skin (melanocytes) are absent or demonstrate lack of activity. As a result, lighter depigmented patches of skin (target lesions) appear in different parts of the body due the lack of melanin (pigment). The exact cause of vitiligo is unknown, but it is generally recognised that an autoimmune component plays a role in this disease. Between 0.1-2% of the global population is affected by vitiligo affecting all races. Vitiligo causes significant psychological and emotional distress.
Vitiligo is traditionally separated into two clinical forms: nonsegmental, or generalised vitiligo and segmental vitiligo (SV), which present with distinctive clinical features and natural histories.
Generalised vitiligo (or just 'vitiligo', previously referred to as 'nonsegmental vitiligo')* is the most common form of the disease, accounting for 72-95% of the cases. The vitiliginous lesions are usually symmetrically distributed and new patches may appear throughout the patient’s life. The disease is progressive with flare-ups. Vitiligo is frequently associated with personal or family history of auto-immunity.
SV is characterised by a unilateral distribution that may totally or partially match a dermatome (area of skin with innervation from a single spinal nerve) and has an earlier onset and a rapid spread. SV occurs in a minority of patients and is thought to be more frequent in pediatric patients; it may account for 30% of childhood cases. Auto-immune association is rare with SV.
The main goal of treating vitiligo is to achieve an arrest of the depigmentation or even arrive at repigmentation of the unpigmented lesions. Many treatment options exist but clinical challenges persist, as not all patients respond to available therapies and relapse is common.
CLINUVEL commenced a pilot Phase II trial of SCENESSE® (afamelanotide 16mg) as a repigmentation therapy in patients with generalised vitiligo in the USA and Europe in the second quarter of 2011. SCENESSE® is being evaluated for its ability to activate melanocytes within the vitiliginous lesions and achieve repigmentation in combination with NB-UVB in patients with vitiligo. The first treatment results from this program, study CUV102, were announced in December 2012. A Phase IIb study of the drug commenced in Singapore in 2014.
The introduction of SCENESSE® (afamelanotide 16mg) in vitiligo treatment
An introductory video on our vitiligo program; view on our YouTube channel here (opens new window).
To read more about vitiligo, see this page
Resources and associations
Further information on vitiligo can be found on the CLINUVEL Science of Skin Vitiligo page.
- Vitiligo Support International (US and global)
- National Vitiligo Foundation (US)
- The Vitiligo Society (UK)
- Vitiligo European Task Force (VETF)
- The Netherlands Institute for Pigment Disorders
- Portal of the German vitiligo self-help groups
- The Vitiligo Society of South Africa
- Vitiligo friends (online community)
* Since the commencement of CLINUVEL's clinical program it has been agreed by the international medical community that ‘nonsegmental vitiligo’ no longer be used to describe the most common form of the disease, which is now referred to as ‘vitiligo’.